About RHI Magnesita RHI Magnesita is the leading global supplier of high-grade refractory products, systems and solutions which are critical for high-temperature processes exceeding 1,200°C in a wide range of industries, including steel, cement, non-ferrous metals and glass. With a vertically integrated value chain, from raw materials to refractory products and full performance-based solutions, RHI Magnesita serves customers around the world, with around 12,000 employees in 28 main production sites and more than 70 sales offices. RHI Magnesita intends to build on its leadership in revenue, scale, product portfolio and diversified geographic presence to expand further in high growth markets. The Group maintains a premium listing on the Official list of the London Stock Exchange (symbol: RHIM) and is a constituent of the FTSE 250 index, with a secondary listing on the Vienna Stock Exchange (Wiener Börse). For more information please visit: www.rhimagnesi
SYNLAB sets final offer price for IPO at EUR 18.00 per share
Search jobs
DGAP-News: Synlab AG / Key word(s): IPO
27.04.2021 / 22:50
Total offer volume of EUR 772 million, assuming full exercise of Greenshoe option
Offer price implies a total market capitalisation of EUR 4 billion and a total enterprise value of EUR 5.9 billion
Free float expected to amount to 19% of outstanding share capital, if Greenshoe option is fully exercised
First day of trading on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange under the trading symbol SYAB is planned for Friday, 30 April 2021
SYNLAB (the Company ), the largest European clinical laboratory and medical diagnostic services company, has set the final offer price for its initial public offering (the Offering ) at EUR 18.00 per share. Assuming full exercise of the Greenshoe option and based on the final offer price, the total offer volume amounts to EUR 772 million. This comprises gross primary proceeds of EU
Disclaimer
This release is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada or Japan. It does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Japan. The shares mentioned herein have not been, and will not be, registered under the US Securities Act of 1933, as amended (the Securities Act ). The shares may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. There will be no public offer of shares of SYNLAB AG (the Company ) in the United States.
Disclaimer
This release is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada or Japan. It does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Japan. The shares mentioned herein have not been, and will not be, registered under the US Securities Act of 1933, as amended (the Securities Act ). The shares may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. There will be no public offer of shares of SYNLAB AG (the Company ) in the United States.